Liposarcoma is a rare type of cancer that develops in fat cells, most commonly appearing in the limbs or the abdomen. While treatment approaches depend on the tumor’s location, size, and specific subtype, managing this disease often requires a combination of surgery, radiation therapy, and in some cases, specialized medications. Because different types of liposarcoma behave differently—some growing slowly and others spreading aggressively—an individualized treatment plan is essential for each patient.

How Treatment Decisions Are Made for This Rare Cancer

When someone receives a diagnosis of liposarcoma, the path forward isn’t always straightforward. This cancer isn’t a single disease but rather a group of related conditions that all start in fat cells. The treatment journey begins with understanding exactly what type of liposarcoma is present, where it’s located in the body, and how far it may have spread. These factors shape every decision that follows.^[1]

The main goal of treatment is to remove the cancer completely whenever possible, prevent it from coming back, and help patients maintain the best quality of life. Some liposarcomas grow very slowly and rarely spread beyond their original location. Others can be more aggressive, growing quickly and potentially moving to other parts of the body. This wide range of behaviors means that what works for one patient may not be the best approach for another.^[2]

Medical societies and cancer centers have developed guidelines based on years of research and clinical experience. These recommendations help doctors choose the most appropriate treatments. At the same time, researchers continue to explore new therapies through clinical trials—carefully controlled studies that test promising new treatments before they become widely available. For patients with liposarcoma, especially those with advanced or recurring disease, these trials may offer access to cutting-edge approaches that aren’t yet part of standard care.^[11]

Treatment planning involves more than just the cancer itself. Doctors must consider the patient’s overall health, age, other medical conditions, and personal preferences. A tumor located deep in the abdomen requires a different approach than one in the leg. A slowly growing tumor in an older patient might be managed differently than an aggressive one in a younger person. This personalized approach ensures that treatment is not only effective but also appropriate for each individual’s circumstances.^[9]

Standard Treatment Approaches

Surgery stands as the cornerstone of liposarcoma treatment. The primary objective is to remove the entire tumor along with a margin of healthy tissue surrounding it. This margin helps ensure that no cancer cells are left behind. Surgeons aim to preserve as much normal tissue and organ function as possible while achieving complete removal. When a liposarcoma is located in an arm or leg, the operation may be relatively straightforward. However, when the tumor develops in the abdomen, particularly in the space behind the abdominal organs called the retroperitoneum, surgery becomes more complex because the tumor may grow around vital structures.^[9]

The type and extent of surgery depend on several factors. For well-differentiated liposarcomas, which grow slowly and rarely spread, complete surgical removal often provides excellent long-term results. These tumors can become quite large before they’re discovered, especially when they’re located deep inside the body. Despite their size, they typically remain confined to their original location, making them good candidates for surgical treatment. The challenge lies in removing them completely without damaging nearby organs.^[2]

After surgery, patients typically need time to heal. The recovery period varies depending on the tumor’s location and the extent of the operation. Someone who had a tumor removed from their leg might need physical therapy to regain strength and mobility. A patient who underwent abdominal surgery may need several weeks before returning to normal activities. Pain management is an important part of recovery, and doctors can prescribe medications to keep patients comfortable during healing.^[17]

Radiation therapy uses powerful energy beams to kill cancer cells or stop them from growing. It plays an important role in treating liposarcoma, especially when used alongside surgery. Radiation can be given before surgery to shrink a tumor, making it easier to remove. More commonly, it’s used after surgery to eliminate any cancer cells that might remain in the surrounding tissues. This approach, called adjuvant radiation, helps reduce the risk of the cancer returning in the same area.^[9]

The radiation beam is carefully aimed at the tumor site while protecting healthy tissue as much as possible. Treatment typically involves daily sessions over several weeks. Each session lasts only a few minutes, though the total course of radiation may continue for five to six weeks. Some patients experience side effects from radiation, and these depend largely on which part of the body is being treated. When radiation is directed at an arm or leg, the skin in that area may become red or irritated, similar to a sunburn. Fatigue is common during treatment. When radiation targets the abdomen, patients might experience nausea or changes in bowel habits.^[17]

Chemotherapy involves using drugs to kill cancer cells throughout the body. Unlike surgery or radiation, which target specific areas, chemotherapy travels through the bloodstream and can reach cancer cells wherever they may be. However, not all liposarcomas respond equally well to chemotherapy. Research has shown that certain subtypes, particularly myxoid liposarcoma, tend to be more sensitive to these drugs than others. Well-differentiated and dedifferentiated liposarcomas often show limited response to traditional chemotherapy drugs.^[12]

When chemotherapy is recommended, it’s typically for patients with advanced disease that has spread to other parts of the body, or for those whose tumors cannot be completely removed with surgery. The specific drugs used depend on the type of liposarcoma and the patient’s overall health. Common chemotherapy agents for liposarcoma include combinations that have shown effectiveness in soft tissue sarcomas. Treatment usually involves cycles—periods of receiving the drugs followed by rest periods to allow the body to recover.^[11]

Chemotherapy can cause various side effects because it affects not only cancer cells but also rapidly dividing normal cells. Patients may experience nausea, loss of appetite, hair loss, mouth sores, and fatigue. The bone marrow, which produces blood cells, can also be affected, leading to lower counts of red blood cells, white blood cells, and platelets. This can increase the risk of infections, anemia, and bleeding problems. Doctors monitor blood counts closely during chemotherapy and can adjust treatment or provide supportive medications to manage these effects.^[17]

Treatment in Clinical Trials

While standard treatments form the foundation of liposarcoma care, researchers have been working to develop new and more targeted therapies. These experimental approaches are tested in clinical trials, which follow strict protocols to ensure patient safety while evaluating whether new treatments are effective. For patients with liposarcoma, especially those with disease that has spread or returned after initial treatment, participating in a clinical trial may provide access to promising therapies not yet available outside of research settings.^[11]

One significant advancement in recent years has been the approval of trabectedin, marketed under the brand name Yondelis. This drug was approved in the United States in 2015 specifically for patients with unresectable or metastatic liposarcoma or leiomyosarcoma who had already received prior treatment containing an anthracycline, a type of chemotherapy drug. Trabectedin is an alkylating agent, meaning it works by binding to DNA in cancer cells and interfering with their ability to divide and grow. The approval was based on a large Phase III trial involving 518 patients that demonstrated a significant improvement in progression-free survival—the length of time patients lived without their cancer getting worse—compared to another chemotherapy drug called dacarbazine. Patients receiving trabectedin had a median progression-free survival of 4.2 months compared to 1.5 months with dacarbazine, though the drug did not improve overall survival.^[12]

Another drug that has shown promise for liposarcoma is eribulin, sold as Halaven. The U.S. Food and Drug Administration approved this medication in 2016 for patients with unresectable or metastatic liposarcoma who had previously received anthracycline-based chemotherapy. Eribulin is a microtubule inhibitor, which means it prevents cancer cells from dividing by interfering with structures called microtubules that are essential for cell division. The approval was particularly notable because it was based on results from a subgroup of 143 liposarcoma patients in a larger trial. These patients showed a significant survival benefit—those receiving eribulin lived a median of 15.6 months compared to 8.4 months for those receiving dacarbazine, representing a 7-month improvement. However, eribulin came with more side effects than dacarbazine, including neutropenia (low white blood cell counts), fever, peripheral neuropathy (nerve damage causing numbness and tingling), and hair loss.^[12]

Researchers are also exploring drugs that target specific molecular abnormalities found in liposarcoma cells. One area of investigation involves CDK4 inhibitors. Well-differentiated and dedifferentiated liposarcomas often have amplifications of genes called MDM2 and CDK4, which are involved in controlling cell growth. When these genes become overactive, cells can divide uncontrollably. Scientists have developed drugs that can block the CDK4 protein, potentially slowing or stopping tumor growth. Palbociclib is one such drug that has been studied in clinical trials for liposarcoma. While it’s already approved for certain types of breast cancer, its effectiveness in liposarcoma is still being evaluated in research studies.^[11]

Another promising area of research involves understanding the unique molecular features of myxoid liposarcoma. This subtype has a characteristic genetic abnormality—a fusion between two genes that creates an abnormal protein. Researchers are working to develop therapies that specifically target this fusion protein or the pathways it affects. Because myxoid liposarcoma tends to be more responsive to chemotherapy than other liposarcoma subtypes, there’s particular interest in identifying which drugs work best for this specific type.^[11]

Clinical trials are conducted in phases, each designed to answer specific questions. Phase I trials primarily focus on safety—researchers determine what doses can be given safely and what side effects might occur. Phase II trials examine whether the treatment shows signs of effectiveness against the cancer and continue to monitor safety. Phase III trials compare the new treatment to current standard treatments to determine if it offers better outcomes. Patients considering a clinical trial should discuss the potential benefits and risks with their medical team. Trials may be available at major cancer centers in the United States, Europe, and other regions around the world.^[11]

Eligibility for clinical trials depends on many factors, including the type and stage of liposarcoma, previous treatments received, overall health status, and sometimes specific genetic features of the tumor. Patients interested in clinical trials can work with their oncology team to identify appropriate studies. Many cancer centers maintain registries of open trials, and organizations dedicated to sarcoma research can help connect patients with relevant studies.^[13]

Most common treatment methods

• Surgery
  • Complete surgical removal of the tumor with surrounding healthy tissue margins
  • The primary and most effective treatment approach for liposarcoma
  • May involve complex procedures for tumors located in the retroperitoneum or near vital organs
  • Goal is to remove all cancer cells while preserving organ function and normal tissue
• Radiation Therapy
  • Uses high-energy beams to kill cancer cells or prevent their growth
  • Often given after surgery to eliminate remaining cancer cells and reduce recurrence risk
  • May be used before surgery to shrink large tumors
  • Treatment typically involves daily sessions over several weeks
  • Myxoid liposarcoma shows particular sensitivity to radiation
• Chemotherapy
  • Systemic treatment using drugs that travel throughout the bloodstream
  • Myxoid liposarcoma subtypes show better response than well-differentiated or dedifferentiated types
  • Typically reserved for advanced disease or tumors that cannot be completely removed surgically
  • Administered in cycles with rest periods between treatments
• Targeted Therapy
  • Trabectedin (Yondelis) approved for unresectable or metastatic liposarcoma after prior anthracycline treatment
  • Eribulin (Halaven) approved for advanced liposarcoma in patients previously treated with anthracyclines
  • Works by targeting specific molecular pathways in cancer cells
  • Offers alternative options for patients with advanced disease
• Clinical Trial Therapies
  • CDK4 inhibitors like palbociclib targeting specific genetic abnormalities in liposarcoma cells
  • Drugs designed to target fusion proteins found in myxoid liposarcoma
  • Combination therapies testing new drug combinations
  • Available at major cancer centers and through specialized sarcoma programs